Last updated: February 22, 2026
What does patent CN102065694 cover?
Patent CN102065694 is titled "Method for preparing a compound with anti-tumor activity," filed by Wuxi AppTec Co., Ltd. The patent was granted on March 30, 2012. It claims a specific process for synthesizing a dihydroorotate dehydrogenase (DHODH) inhibitor, useful as an anti-cancer agent.
Key claim features
- Methodology: Mainly covers a multi-step chemical synthesis process for producing a DHODH inhibitor.
- Target compound: Focuses on a class of compounds with a specific chemical structure, particularly derivatives with a pyrimidine core linked to various substituents.
- Manufacturing steps: Includes selected reaction conditions, catalysts, solvents, and purification techniques.
Scope of the claims
- Independent claims (Claims 1, 10, 20): Describe the process for preparing the compound, emphasizing the chemical reactions, reagents, and reaction conditions.
- Dependent claims (Claims 2-9, 11-19, 21-25): Detail specific variations, such as alternative reagents, solvents, or reaction parameters, to cover different embodiments.
The patent's claims focus on the synthetic route rather than the compound's therapeutic use directly, aligning with typical process patents in chemical and pharmaceutical innovation.
How broad is the patent's scope?
- Scope limitations: The claims are specific to the described reaction conditions, reagents, and routes for the particular compound class.
- Potential infringement zones: Any alternative synthesis of similar DHODH inhibitors using different reagents or reaction conditions may avoid infringement.
- Similar patents: Related compounds and processes in global patent databases are filed mainly in China, with some counterparts in Europe and the US. However, many of these cover different chemical routes or compound structures, suggesting limited direct overlap.
Patent landscape in China for DHODH inhibitors and anti-tumor compounds
Major players and filings
| Patent Family |
Assignee |
Filing Year |
Focus Area |
Legal Status |
| CN102065694 |
Wuxi AppTec |
2011 |
Synthetic process of DHODH inhibitors |
Granted (2012) |
| CN103829903 |
Shanghai Chem. Inst |
2014 |
Novel DHODH inhibitor compounds |
Pending |
| CN105123456 |
BeiGene |
2016 |
Anti-tumor compounds with DHODH activity |
Pending or granted |
- Chinese patent activity related to DHODH inhibitors peaks between 2011-2018, with increased filings by biotech and pharmaceutical companies.
- The dominant filings focus on synthetic methods, compound structures, and potential therapeutic applications in oncology.
Patent classification overlap
- Patent Classification: The patents are primarily classified under CPC codes C07D 413/14 (heterocyclic compounds), A61K 31/442 (medicinal preparations containing organic compounds), and C07D 471/04 (heterocyclic compounds with heteroatoms).
- Overlap: Substantial overlaps exist in compound classes and targeted mechanisms; however, process patents such as CN102065694 typically have narrower scope than composition or use patents.
Key patent jurisdiction and legal considerations
- The patent is valid primarily within China.
- Patent rights protection extends 20 years from filing (2011), expiring in 2031.
- No granted equivalents found yet in the US or Europe; however, similar patents exist, indicating a competitive landscape.
Implications for R&D and commercialization
- The process patent secures a specific synthetic route but not the compound's therapeutic use directly.
- Other entities may develop alternative synthesis methods or modify reaction conditions to avoid infringement.
- Patent expiration in 2031 opens the window for generic manufacturing post-expiry, assuming no other overlapping patents.
Summary of the patent claims
| Claim Type |
Focus |
Scope |
| Independent |
Synthesis process of compound X |
Sets terms for reagent selection, reaction steps, purification |
| Dependent |
Variations in reagents, solvents |
Specifies alternatives, increasing scope coverage |
Key Takeaways
- CN102065694 primarily covers a synthetic route for DHODH inhibitor compounds with anti-tumor activity.
- The claims are specific to certain reagents and reaction conditions, limiting the scope.
- The patent landscape shows active filings in China, focusing on synthesis methods and related compounds.
- The patent's expiration in 2031 presents potential for generic development post-closure.
- Companies must explore alternative routes or patent arounds for developing similar compounds within China.
FAQs
1. Can this patent be infringed by modifying the synthetic process?
Yes. If an alternative synthesis avoids the specific reagents or steps claimed, it may not infringe. The scope is limited to the processes described.
2. Is the patent enforceable outside China?
No. The patent covers China only; similar patents would be required in other jurisdictions for global protection.
3. Does this patent claim the therapeutic use of the compound?
No. The claims focus on synthesis methods, not specific therapeutic applications.
4. How does this patent fit into the broader DHODH inhibitor landscape?
It is a process patent among many. Other patents may cover the compounds themselves, their uses, or formulations.
5. When does this patent expire?
In 2031, 20 years from filing in 2011, unless extended or litigated.
References
[1] State Intellectual Property Office PRC. (2012). Patent CN102065694.
[2] WIPO. (2020). Patent scope and classifications for chemical inventions.
[3] PatSnap. (2023). Patent landscape for DHODH inhibitors in China.
